联环药业(600513.SH)：子公司收到药品GMP符合性检查结果

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) has successfully passed the GMP compliance inspection for its newly established oral solution production line, indicating its capability to meet drug quality requirements and support market demand [1] Summary by Relevant Sections - GMP Compliance Inspection - Lianhuan Pharmaceutical (Anqing) Co., Ltd. received the GMP compliance inspection notice from the Anhui Provincial Drug Administration, marking the first successful inspection of the new oral solution production line [1] - Investment in Production Line - The investment in the oral solution production line amounts to approximately RMB 7.5 million, with the data being unaudited [1] - Production Capability - The successful GMP compliance inspection signifies that Lianhuan (Anqing) has officially established production capabilities that meet drug quality standards, laying a solid foundation to meet market demand for related drugs [1] - Impact on Company Performance - The GMP compliance inspection results are not expected to have a significant impact on the company's performance [1]